Schizophrenia
Page 1 • 2 itemsAccess global pharma market intelligence on schizophrenia treatments, clinical trials, regulatory updates, and investment opportunities. Stay ahead in CNS drug development.
Neurosterix NTX-253 Schizophrenia Drug Phase 1 Trial on Track for Q2 2026 Completion
Addex spin-out Neurosterix remains on schedule to complete Phase 1 clinical study of NTX-253 for schizophrenia treatment by Q2 2026.
Neurosterix NTX-253 Phase 1 Schizophrenia Trial On Track for Q2 2026 Completion
Addex spin-out Neurosterix progresses NTX-253 Phase 1 clinical study for schizophrenia treatment, targeting Q2 2026 completion milestone.